HRP20231440T1 - Protutijela koja neutraliziraju virus hepatitisa b i njihova upotreba - Google Patents
Protutijela koja neutraliziraju virus hepatitisa b i njihova upotreba Download PDFInfo
- Publication number
- HRP20231440T1 HRP20231440T1 HRP20231440TT HRP20231440T HRP20231440T1 HR P20231440 T1 HRP20231440 T1 HR P20231440T1 HR P20231440T T HRP20231440T T HR P20231440TT HR P20231440 T HRP20231440 T HR P20231440T HR P20231440 T1 HRP20231440 T1 HR P20231440T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- vector
- polynucleotide
- subject
- hepatitis
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 208000002672 hepatitis B Diseases 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 229940123066 Polymerase inhibitor Drugs 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 230000016784 immunoglobulin production Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 101710142246 External core antigen Proteins 0.000 claims 1
- 208000005331 Hepatitis D Diseases 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 229960001997 adefovir Drugs 0.000 claims 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 208000016350 chronic hepatitis B virus infection Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960000980 entecavir Drugs 0.000 claims 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 229940126546 immune checkpoint molecule Drugs 0.000 claims 1
- 229960001627 lamivudine Drugs 0.000 claims 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 229960005311 telbivudine Drugs 0.000 claims 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims 1
- 229960004556 tenofovir Drugs 0.000 claims 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Claims (15)
1. Izolirano protutijelo koje veže HBsAg koje sadrži:
(i) teški lanac (HC) koji sadrži aminokiselinsku sekvencu prema SEQ ID NO:91; i
(ii) laki lanac (LC) koji sadrži aminokiselinsku sekvencu prema SEQ ID NO:93.
2. Protutijelo prema zahtjevu 1, naznačeno time što je protutijelo sposobno vezati HBsAg genotipa odabranog između HBsAg genotipova A, B, C, D, E, F, G, H, I, i J, ili bilo koju njihovu kombinaciju.
3. Protutijelo prema zahtjevu 1 ili zahtjevu 2, naznačeno time što je protutijelo sposobno smanjiti koncentraciju DNA virusa hepatitisa B u serumu (HBV) kod sisavca koji ima HBV infekciju.
4. Protutijelo prema bilo kojem od zahtjeva 1-3, naznačeno time što je protutijelo sposobno smanjiti koncentraciju HBsAg u serumu kod sisavca koji ima HBV infekciju.
5. Protutijelo prema bilo kojem od zahtjeva 1-4, naznačeno time što je protutijelo sposobno smanjiti koncentraciju HBeAg u serumu kod sisavca koji ima HBV infekciju.
6. Protutijelo prema bilo kojem od zahtjeva 1-5, naznačeno time što je protutijelo sposobno smanjiti koncentraciju HBcrAg u serumu kod sisavca koji ima HBV infekciju.
7. Izolirani polinukleotid koji sadrži nukleotidnu sekvencu koja kodira protutijelo prema bilo kojem od zahtjeva 1-6, po izboru, naznačen time što je nukleotidna sekvenca kodon optimiziran za ekspresiju u stanici domaćinu.
8. Polinukleotid prema zahtjevu 7, naznačen time što sadrži (i) nukleotidnu sekvencu koja ima najmanje 80% identičnosti s nukleotidnom sekvencom prema bilo kojoj od SEQ ID NO:103 i SEQ ID NO:105, ili (ii) VH-kodirajuću nukleotidnu sekvencu prema SEQ ID NO:103, i VL- kodirajuću nukleotidnu sekvencu prema SEQ ID NO:105.
9. Vektor naznačen time što sadrži polinukleotid prema zahtjevu 7 ili 8, naznačen time što, po izboru, vektor sadrži lentivirusni vektor ili retrovirusni vektor.
10. Stanica domaćina naznačena time što sadrži heterologni polinukleotid prema zahtjevu 7 ili 8.
11. Farmaceutski pripravak naznačen time što sadrži:
(i) protutijelo prema bilo kojem od zahtjeva 1-6;
(ii) polinukleotid prema zahtjevu 7 ili 8;
(iii) vektor prema zahtjevu 9;
(iv) stanicu domaćina prema zahtjevu 10; ili
(v) bilo koju kombinaciju (i)-(iv);
i farmaceutski prihvatljivu pomoćnu tvar, razrjeđivač ili nosač.
12. Postupak proizvodnje protutijela prema bilo kojem od zahtjeva 1-6, naznačen time što obuhvaća uzgoj stanice domaćina prema zahtjevu 10 pod uvjetima i tijekom vremena dovoljnog za proizvodnju protutijela.
13. (i) Protutijelo prema bilo kojem od zahtjeva 1-6; (ii) polinukleotid prema zahtjevu 7 ili 8; (iii) vektor prema zahtjevu 9; (iv) stanica domaćina prema zahtjevu 10; i/ili (v) farmaceutski pripravak prema zahtjevu 11, za upotrebu u postupku liječenja, prevencije i/ili ublažavanja infekcije hepatitisom B i/ili hepatitisom D kod subjekta, koji se sastoji od davanja subjektu učinkovite količine: (i), (ii), (iii), (iv), ili (v).
14. (i) Protutijelo; (ii) polinukleotid; (iii) vektor; (iv) stanica domaćin; i/ili (v) farmaceutski pripravak, za upotrebu prema zahtjevu 13, koji dalje uključuje davanje subjektu jednog ili više od: (vi) inhibitora polimeraze, pri čemu inhibitor polimeraze izborno sadrži lamivudin, adefovir, entekavir, telbivudin, tenofovir, ili bilo koju njihovu kombinaciju; (vii) interferon, pri čemu interferon izborno sadrži IFNbeta i/ili IFNalfa; (viii) inhibitor kontrolne točke, pri čemu inhibitor kontrolne točke po izboru sadrži anti-PD-1 protutijelo ili njegov fragment koji veže antigen, anti-PD-L1 protutijelo ili njegov fragment koji veže antigen, i/ili anti-CTLA4 protutijelo ili njegov fragment koji veže antigen; (ix) agonist molekule stimulativne imunološke kontrolne točke; ili (x) bilo koju kombinaciju (vi)-(ix).
15. (i) Protutijelo; (ii) polinukleotid; (iii) vektor; (iv) stanica domaćin; i/ili (v) farmaceutski pripravak za upotrebu prema zahtjevu 13 ili 14, naznačeni time što je infekcija hepatitisom B kronična infekcija hepatitisom B; i/ili subjekt je primio transplantaciju jetre, subjekt nije imuniziran protiv hepatitisa B, subjekt je novorođenče, i/ili subjekt je podvrgnut ili je bio podvrgnut hemodijalizi.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782274P | 2018-12-19 | 2018-12-19 | |
| US201962860085P | 2019-06-11 | 2019-06-11 | |
| EP19839558.4A EP3898668B1 (en) | 2018-12-19 | 2019-12-18 | Antibodies that neutralize hepatitis b virus and uses thereof |
| PCT/US2019/067216 WO2020132091A2 (en) | 2018-12-19 | 2019-12-18 | Antibodies that neutralize hepatitis b virus and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231440T1 true HRP20231440T1 (hr) | 2024-03-01 |
Family
ID=69182688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231440TT HRP20231440T1 (hr) | 2018-12-19 | 2019-12-18 | Protutijela koja neutraliziraju virus hepatitisa b i njihova upotreba |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20220127336A1 (hr) |
| EP (2) | EP4292659A3 (hr) |
| JP (1) | JP2022514940A (hr) |
| KR (1) | KR20210126558A (hr) |
| CN (1) | CN113544148B (hr) |
| AU (1) | AU2019403245A1 (hr) |
| BR (1) | BR112021012094A2 (hr) |
| CA (1) | CA3121004A1 (hr) |
| DK (1) | DK3898668T3 (hr) |
| ES (1) | ES2961791T3 (hr) |
| FI (1) | FI3898668T3 (hr) |
| HR (1) | HRP20231440T1 (hr) |
| HU (1) | HUE063732T2 (hr) |
| IL (1) | IL284044A (hr) |
| LT (1) | LT3898668T (hr) |
| MX (1) | MX2021006756A (hr) |
| PL (1) | PL3898668T3 (hr) |
| PT (1) | PT3898668T (hr) |
| SG (1) | SG11202106483WA (hr) |
| SI (1) | SI3898668T1 (hr) |
| TW (1) | TW202039547A (hr) |
| WO (1) | WO2020132091A2 (hr) |
| ZA (1) | ZA202104213B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3152511A1 (en) * | 2019-08-29 | 2021-03-04 | Vir Biotechnology, Inc. | Antibody compositions and methods for treating hepatitis b virus infection |
| AU2021296848A1 (en) | 2020-06-24 | 2023-02-09 | Humabs Biomed Sa | Engineered hepatitis B virus neutralizing antibodies and uses thereof |
| CN116635024A (zh) * | 2020-10-14 | 2023-08-22 | 维里迪安治疗公司 | 用于治疗甲状腺眼病的组合物和方法 |
| KR20230124550A (ko) * | 2020-10-14 | 2023-08-25 | 비리디안 쎄라퓨틱스, 인크. | 갑상선 눈 질환의 치료를 위한 조성물 및 방법 |
| WO2022164805A1 (en) * | 2021-01-26 | 2022-08-04 | Vir Biotechnology, Inc. | Compositions and methods for treating hepatitis b virus infection |
| WO2023225599A2 (en) * | 2022-05-19 | 2023-11-23 | Vir Biotechnology, Inc. | Compositions and methods for treating hepatitis d virus (hdv) infection and associated diseases |
| WO2023225598A2 (en) * | 2022-05-19 | 2023-11-23 | Vir Biotechnology, Inc. | Compositions and methods for treating hepatitis b virus (hbv) infection and hbv-associated diseases |
| WO2023230439A1 (en) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| EP1597280B2 (en) | 2003-02-26 | 2016-08-24 | Institute for Research in Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| WO2005000899A2 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| NZ581395A (en) | 2007-05-14 | 2012-08-31 | Biogen Idec Inc | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| ES2525346T3 (es) | 2008-10-22 | 2014-12-22 | Institute For Research In Biomedicine | Métodos para producir anticuerpos a partir de células plasmáticas |
| EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| NZ621170A (en) * | 2009-05-13 | 2015-08-28 | Genzyme Corp | Anti-human cd52 immunoglobulins |
| JP6120848B2 (ja) | 2011-08-15 | 2017-04-26 | メディミューン，エルエルシー | 抗ｂ７−ｈ４抗体およびその使用 |
| GB201216649D0 (en) * | 2012-09-18 | 2012-10-31 | Univ Birmingham | Agents and methods |
| BR112015014063A2 (pt) | 2012-12-19 | 2018-10-30 | Amplimmune Inc | anticorpos anti-b7-h4 humano e seus usos. |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CN113698488A (zh) | 2014-09-12 | 2021-11-26 | 基因泰克公司 | 抗-b7-h4抗体及免疫缀合物 |
| JP2017531427A (ja) | 2014-10-03 | 2017-10-26 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法 |
| US10227408B2 (en) | 2015-02-19 | 2019-03-12 | Compugen Ltd. | Anti-PVRIG antibodies and methods of use |
| US10301377B2 (en) * | 2015-02-24 | 2019-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| WO2017059878A1 (en) * | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| EP3390441B1 (en) * | 2015-12-15 | 2021-08-25 | Gilead Sciences, Inc. | Human immunodeficiency virus neutralizing antibodies |
| WO2018207023A2 (en) * | 2017-05-10 | 2018-11-15 | Albajuna Therapeutics, S.L. | Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity |
-
2019
- 2019-12-18 AU AU2019403245A patent/AU2019403245A1/en active Pending
- 2019-12-18 FI FIEP19839558.4T patent/FI3898668T3/fi active
- 2019-12-18 EP EP23193597.4A patent/EP4292659A3/en active Pending
- 2019-12-18 TW TW108146488A patent/TW202039547A/zh unknown
- 2019-12-18 PT PT198395584T patent/PT3898668T/pt unknown
- 2019-12-18 CN CN201980092549.9A patent/CN113544148B/zh active Active
- 2019-12-18 HR HRP20231440TT patent/HRP20231440T1/hr unknown
- 2019-12-18 JP JP2021536337A patent/JP2022514940A/ja active Pending
- 2019-12-18 CA CA3121004A patent/CA3121004A1/en active Pending
- 2019-12-18 WO PCT/US2019/067216 patent/WO2020132091A2/en active Application Filing
- 2019-12-18 ES ES19839558T patent/ES2961791T3/es active Active
- 2019-12-18 US US17/413,696 patent/US20220127336A1/en active Pending
- 2019-12-18 MX MX2021006756A patent/MX2021006756A/es unknown
- 2019-12-18 EP EP19839558.4A patent/EP3898668B1/en active Active
- 2019-12-18 LT LTEPPCT/US2019/067216T patent/LT3898668T/lt unknown
- 2019-12-18 PL PL19839558.4T patent/PL3898668T3/pl unknown
- 2019-12-18 SG SG11202106483WA patent/SG11202106483WA/en unknown
- 2019-12-18 DK DK19839558.4T patent/DK3898668T3/da active
- 2019-12-18 KR KR1020217022590A patent/KR20210126558A/ko unknown
- 2019-12-18 BR BR112021012094-7A patent/BR112021012094A2/pt unknown
- 2019-12-18 HU HUE19839558A patent/HUE063732T2/hu unknown
- 2019-12-18 SI SI201930652T patent/SI3898668T1/sl unknown
-
2021
- 2021-06-15 IL IL284044A patent/IL284044A/en unknown
- 2021-06-18 ZA ZA2021/04213A patent/ZA202104213B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT3898668T (pt) | 2023-12-06 |
| WO2020132091A3 (en) | 2020-10-15 |
| ES2961791T3 (es) | 2024-03-13 |
| PL3898668T3 (pl) | 2024-04-02 |
| HUE063732T2 (hu) | 2024-01-28 |
| LT3898668T (lt) | 2023-11-10 |
| WO2020132091A2 (en) | 2020-06-25 |
| EP4292659A3 (en) | 2024-03-20 |
| CA3121004A1 (en) | 2020-06-25 |
| TW202039547A (zh) | 2020-11-01 |
| EP3898668A2 (en) | 2021-10-27 |
| WO2020132091A9 (en) | 2021-02-25 |
| MX2021006756A (es) | 2021-09-28 |
| AU2019403245A1 (en) | 2021-07-22 |
| SG11202106483WA (en) | 2021-07-29 |
| EP3898668B1 (en) | 2023-08-30 |
| CN113544148A (zh) | 2021-10-22 |
| BR112021012094A2 (pt) | 2021-08-31 |
| IL284044A (en) | 2021-08-31 |
| SI3898668T1 (sl) | 2024-02-29 |
| ZA202104213B (en) | 2023-12-20 |
| KR20210126558A (ko) | 2021-10-20 |
| JP2022514940A (ja) | 2022-02-16 |
| CN113544148B (zh) | 2024-04-05 |
| EP4292659A2 (en) | 2023-12-20 |
| DK3898668T3 (da) | 2023-11-13 |
| FI3898668T3 (fi) | 2023-11-28 |
| US20220127336A1 (en) | 2022-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231440T1 (hr) | Protutijela koja neutraliziraju virus hepatitisa b i njihova upotreba | |
| JP7375062B2 (ja) | 抗体、使用、及び方法 | |
| JP6942465B2 (ja) | 抗ｐｄｌ１抗体製剤 | |
| US9234043B1 (en) | Anti-human OX40L antibodies | |
| AU2016238246B2 (en) | Multi-valent hepatitis B virus antigen binding molecules and uses thereof | |
| JP2019055962A (ja) | 抗体製剤 | |
| JP2012519706A (ja) | 抗体製剤 | |
| KR20150129033A (ko) | 저 산성 종 조성물 및 이의 제조 및 사용 방법 | |
| WO2013177118A2 (en) | Novel purification of non-human antibodies using protein a affinity chromatography | |
| AU2016227493B2 (en) | Antibodies, uses & methods | |
| MX2011004200A (es) | Aislamento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a. | |
| MX2011004201A (es) | Desactivacion viral durante purificacion de anticuerpos. | |
| Ceccarelli et al. | Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy | |
| WO2018083248A1 (en) | Antibodies, combinations comprising antibodies, biomarkers, uses & methods | |
| EP3145951A1 (en) | Methods of purifying antibodies | |
| JP2016539925A5 (hr) | ||
| JP2017538786A5 (hr) | ||
| JPWO2020132091A5 (hr) | ||
| CN102757492A (zh) | 全人乙肝表面蛋白单克隆抗体及其在制备预防hbv感染药物中的用途 | |
| US11453717B2 (en) | Trispecific antibodies against IL-17A, IL-17F and other pro-inflammatory molecule | |
| US20210324084A1 (en) | Method for suppression of hepapitis b virus replication and hepapitis b virus surface antigen secretion | |
| JP2004517636A5 (hr) | ||
| RU2021105677A (ru) | Способ подавления репликации вируса гепатита b и секреции поверхностного антигена вируса гепатита b | |
| JP2021008452A (ja) | 抗体精製プロセスにおけるプロテインａクロマトグラフィーのための洗浄溶液の改善 | |
| JPWO2019229699A5 (hr) |